Browse All

Current Filters

CLEAR FILTER x

TITLE

Title
    Author Last Name
      Session Name
        Topic
          Program Number
            Author Institution

              Low Disease Activity Over 4 Years of Ocrelizumab Therapy in Treatment-Naive Patients With Early-Stage Relapsing-Remitting Multiple Sclerosis; the Phase IIIb ENSEMBLE Study

              Author:Bermel, Robert   Hartung, Hans-Peter   Brochet, Bruno   Benedict, Ralph   Berger, Thomas   Carroll, William   Vollmer, Timothy   Holmoy, Trygve   Karabudak, Rana   Killestein, Joep   Nos, Carlos   Patti, Francesco   Perrin Ross, Amy   Vanopdenbosch, Ludo   Wuerfel, Jens   Kuenzel, Thomas   Kadner, Karen   Kulyk, Inessa   Freedman, Mark   

              Session Name:S46: MS Therapeutics and Clinical Decision Making  

              Topic:MS and Inflammatory Disease  

              Program Number:S46.004  

              Author Institution:Mellen Center for MS, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH  Deptartment of Neurology, Heinrich-Heine-University Düsseldorf, Germany, Dusseldorf, Germany  Université de Bordeaux, Neurocentre Magendie INSERM, Bordeaux, France, Bordeaux, France  Jacobs School of Medicine and Biomedical Sciences, Department of Neurology, University of Buffalo, NY, USA, Buffalo, NY  Dept. of Neurology, Medical University of Vienna, Vienna, Austria  Department of Neurology, Sir Charles Gairdner Hospital, Perron Institute for Neurological and Translational Science, The University of Western Australia, Nedlands, Australia, Subiaco, Australia  Department of Neurology, University of Colorado School of Medicine, Aurora, CO, USA, Aurora, CO  Department of Neurology, Akershus University Hospital, Lørenskog, Norway, Lasker, Norway  Department of Neurology, Hacettepe University Faculty of Medicine, Ankara, Turkey, Ankara, Turkey  Department of Neurology, VU University Medical Centre, Amsterdam, The Netherlands, Amsterdam, Netherlands  Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d’Hebron Hospital Universitari, Barcelona, Spain, Barcelona, Spain  Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Neuroscience Section and Multiple Sclerosis Centre, University of Catania PO Policlinico G Rodolico, Catania, Italy, Catania, Italy  Loyola University Chicago, Chicago, IL, USA, Oak Brook, IL  Department of Neurology, AZ Sint-Jan Brugge-Oostende, Brugge, Belgium, Brugge, Belgium  F. Hoffmann-La Roche Ltd, Basel, Switzerland, Basel, Switzerland  University of Ottawa, Department of Medicine and the Ottawa Hospital Research Institute Ottawa, ON, Canada., Ottawa, ON, Canada  

              Infusion-Related Reactions With Ocrelizumab: Risk Factors, Symptom Management and Patient Choices in the ENSEMBLE PLUS Study

              Author:Bermel, Robert   Killestein, Joep   Berger, Thomas   Brochet, Bruno   Carroll, William   Freedman, Mark   Holmoy, Trygve   Karabudak, Rana   Nos, Carlos   Patti, Francesco   Perrin Ross, Amy   Vanopdenbosch, Ludo   Vollmer, Timothy   Buffels, Regine   Kadner, Karen   Bortolami, Oscar   Hartung, Hans-Peter   

              Session Name:P7: MS Therapeutics 1  

              Topic:MS and Inflammatory Disease  

              Program Number:P7.003  

              Author Institution:Mellen Center for MS, Department of Neurology, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH  Department of Neurology, VU University Medical Centre, Amsterdam, The Netherlands, Amsterdam, Netherlands  Department of Neurology, Medical University of Vienna, Vienna, Austria, Vienna, Austria  University of Bordeaux, Bordeaux, France, Bordeaux, France  Department of Neurology, Sir Charles Gairdner Hospital, Perron Institute for Neurological and Translational Science, The University of Western Australia, Nedlands, Australia, Subiaco, Australia  University of Ottawa, Department of Medicine and the Ottawa Hospital Research Institute, Ottawa, ON, Canada, Ottawa, ON, Canada  Department of Neurology, Akershus University Hospital, Lørenskog, Norway, Lasker, Norway  Department of Neurology, Hacettepe University Faculty of Medicine, Ankara, Turkey, Ankara, Turkey  Centre d’Esclerosi Mútiple de Catalunya (Cemcat), Vall d’Hebron Hospital Universitari, Barcelona, Spain, Barcelona, Spain  Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Neuroscience Section and Multiple Sclerosis Centre, University of Catania PO Policlinico G Rodolico, Catania, Italy, Catania, Italy  Loyola University Chicago, Chicago, IL, USA , Oak Brook, IL  Department of Neurology, AZ Sint-Jan Brugge-Oostende, Brugge, Belgium, Brugge, Belgium  Department of Neurology, University of Colorado School of Medicine, Aurora, CO, USA, Aurora, CO  F. Hoffmann-La Roche Ltd, Basel, Switzerland, Toulon, France  F. Hoffmann-La Roche Ltd, Basel, Switzerland, Basel, Switzerland  Department of Neurology, UKD, Centre of Neurology and Neuropsychiatry and LVR-Klinikum, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany, Dusseldorf, Germany